Nektar Therapeutics (NKTR) Accounts Payables (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Accounts Payables of $10.0 million for Q1 2026, down 43.78% year-over-year from $17.8 million in Q1 2025, and down 6.91% quarter-over-quarter from $10.8 million in Q4 2025.
Nektar Therapeutics (NKTR) Accounts Payables (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Accounts Payables history runs 17 years deep, the most recent figure standing at $10.0 million for Q1 2026.
- In Q1 2026, Accounts Payables fell 43.78% year-over-year to $10.0 million; the TTM figure through Mar 2026 stood at $10.0 million (down 43.78% YoY), while the FY2025 annual figure was $10.8 million, down 6.83% from the prior year.
- Accounts Payables for Q1 2026 stood at $10.0 million, down from $10.8 million in the prior quarter.
- The five-year high for Accounts Payables was $17.8 million in Q1 2025, with the low at $2.6 million in Q2 2023.
- The 5-year median for Accounts Payables is $10.0 million (2026), against an average of $9.8 million.
- The sharpest annual moves came in 2023 and 2024: Accounts Payables slumped 78.79% in 2023, then surged 160.86% in 2024.
- Nektar Therapeutics' Accounts Payables stood at $13.0 million in 2022, then dropped by 24.13% to $9.8 million in 2023, then gained by 17.38% to $11.6 million in 2024, then declined by 6.83% to $10.8 million in 2025, then slipped by 6.91% to $10.0 million in 2026.
- Business Quant data shows NKTR's Accounts Payables at $10.0 million in Q1 2026, $10.8 million in Q4 2025, and $15.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | 10.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.03 Mn |
| Dec 31, 2025 | 10.77 Mn |
| Sep 30, 2025 | 15.56 Mn |
| Jun 30, 2025 | 14.28 Mn |
| Mar 31, 2025 | 17.83 Mn |
| Dec 31, 2024 | 11.56 Mn |
| Sep 30, 2024 | 8.58 Mn |
| Jun 30, 2024 | 6.48 Mn |
| Mar 31, 2024 | 8.76 Mn |
| Dec 31, 2023 | 9.85 Mn |
| Sep 30, 2023 | 3.29 Mn |
| Jun 30, 2023 | 2.62 Mn |
| Mar 31, 2023 | 3.70 Mn |
| Dec 31, 2022 | 12.98 Mn |
| Sep 30, 2022 | 5.33 Mn |
| Jun 30, 2022 | 12.35 Mn |
| Mar 31, 2022 | 12.62 Mn |
| Dec 31, 2021 | 9.75 Mn |
| Sep 30, 2021 | 23.66 Mn |
| Jun 30, 2021 | 19.70 Mn |